A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)

• Main Authors: Zoran Popmihajlov (Author), Lei Pang (Author), Elizabeth Brown (Author), Amita Joshi (Author), Shu-Chih Su (Author), Susan S. Kaplan (Author), English D. Willis (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: ZOSTAVAX (ZVL; Zoster Virus Live), is a single dose, live, attenuated vaccine licensed for the prevention of herpes zoster (HZ) and post herpetic neuralgia (PHN) in adults ≥50 years of age. Injection site adverse events (AEs) of erythema, swelling and pain were solicited within 5 days po...